Psychiatry and Neurology, Neurology · Forest Hills, NY
NPI
1316107147
Since 2008
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
10124 Queens Blvd Ste A
Forest Hills, NY, 11375
Phone (718) 261-8881
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.0M
31,941 services
Medicare patients, 2024
905
Average age 76
Drug cost, 2024
$6.0M
15,068 prescriptions
Company payments, 2025
$23K
From 38 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Maria Dolgovina was code J0585 (injection, onabotulinumtoxina, 1 unit), 19,285 times for 42 patients. In total Maria Dolgovina billed 31,941 services in 76 codes, and Medicare paid $1.0M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-06-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0585 Injection, onabotulinumtoxina, 1 unit | Office | 19,285 | 42 | $4.99 | $96K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 1,771 | 277 | $59.12 | $105K |
| J3475 Injection, magnesium sulfate, per 500 mg | Office | 1,075 | 219 | $0.45 | $482 |
| 99214 Office E&M - Established | Office | 1,051 | 443 | $119.05 | $125K |
| 99439 Chronic, Principal, and Transitional Care Management | Office | 904 | 215 | $45.61 | $41K |
| 95886 Electrical Nerve Conductivity | Office | 644 | 295 | $93.84 | $60K |
| 96374 Injection Administration | Office | 573 | 219 | $35.95 | $21K |
| 99213 Office E&M - Established | Office | 496 | 325 | $82.82 | $41K |
| 96372 Injection Administration | Office | 396 | 168 | $13.69 | $5,422 |
| 95911 Electrical Nerve Conductivity | Office | 321 | 291 | $205.28 | $66K |
| 92540 Vision, Hearing, and Speech Services | Office | 275 | 274 | $102.25 | $28K |
| 92537 Test - Miscellaneous | Office | 275 | 274 | $38.10 | $10K |
| 92547 Vision, Hearing, and Speech Services | Office | 274 | 273 | $10.76 | $2,950 |
| 92546 Vision, Hearing, and Speech Services | Office | 271 | 270 | $133.27 | $36K |
| J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 246 | 88 | $1.01 | $247 |
By year: 2022 $887K for 28,182 services; 2023 $910K for 27,326 services; 2024 $1.0M for 31,941 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 139 | 125 | $8.65 | $1,202 |
Medicare prescription drug claims, 2024
In 2024, the drug Maria Dolgovina prescribed most often to Medicare patients was Gabapentin, with 886 prescriptions and refills. In total Maria Dolgovina wrote 15,068 Medicare prescriptions that cost $6.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Gabapentin Generic | 886 | 1,008 | 207 | $7,901 |
| Diclofenac Sodium Generic | 740 | 817 | 161 | $614K |
| Ztlido Lidocaine | 722 | 741 | 156 | $257K |
| Duloxetine Hcl Generic | 666 | 754 | 124 | $11K |
| Meclizine Hcl Generic | 563 | 585 | 144 | $2,504 |
| Nurtec Odt Rimegepant Sulfate | 520 | 525 | 78 | $932K |
| Diclofenac Epolamine Generic | 472 | 488 | 103 | $148K |
| Amitriptyline Hcl Generic | 417 | 455 | 87 | $1,948 |
| Dihydroergotamine Mesylate Generic | 400 | 400 | 50 | $490K |
| Memantine Hcl Er Memantine Hcl | 391 | 470 | 80 | $27K |
| Lidocaine Generic | 387 | 401 | 87 | $28K |
| Doxepin Hcl Generic | 325 | 325 | 62 | $52K |
| Rivastigmine Generic | 318 | 363 | 67 | $40K |
| Ubrelvy Ubrogepant | 276 | 282 | 45 | $415K |
| Pregabalin Generic | 211 | 229 | 50 | $3,107 |
Brand drugs: - claims; generic drugs: 9,866 claims; opioid claims: 378.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Maria Dolgovina $23K ($23K in general payments such as food, travel and fees) from 38 companies. The largest payer was Abbvie Inc. with $16K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.